Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, announced the appointment of Dr. Sandra Silberman as Chief Medical Officer (“CMO”) in charge of New Products.
Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, announced the appointment of Dr. Sandra Silberman as Chief Medical Officer (“CMO”) in charge of New Products.